EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data
Y Fan, X Xu, C Xie - OncoTargets and therapy, 2014 - Taylor & Francis
Introduction Brain metastases are one of the leading causes of death from non-small-cell
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …
[HTML][HTML] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
Background Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy
A Sekine, H Satoh - Medical Oncology, 2017 - Springer
Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations commonly present brain metastases (BM) at the time of NSCLC diagnosis or …
mutations commonly present brain metastases (BM) at the time of NSCLC diagnosis or …
Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis
Q Zhang, X Zhang, H Yan, B Jiang, C Xu… - Thoracic …, 2016 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI s) are
remarkably effective for treating EGFR‐mutant non‐small cell lung cancer (NSCLC) …
remarkably effective for treating EGFR‐mutant non‐small cell lung cancer (NSCLC) …
A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer
Y Fan, Z Huang, L Fang, L Miao, L Gong, H Yu… - Cancer chemotherapy …, 2015 - Springer
Purpose Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of …
kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of …
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis
TH Chiu, PH Tung, CH Huang, JS Ju, ACC Huang… - Scientific Reports, 2022 - nature.com
Abstract Comparison of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) …
TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) …
Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study
Background Non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor
receptor (EGFR) mutations often develop brain metastases. Treatment with EGFR-tyrosine …
receptor (EGFR) mutations often develop brain metastases. Treatment with EGFR-tyrosine …
Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 …
Simple Summary Radiotherapy, in the form of either whole-brain radiotherapy (WBRT) or
stereotactic radiosurgery (SRS), continues as the standard of care for patients of non-small …
stereotactic radiosurgery (SRS), continues as the standard of care for patients of non-small …
First-versus third-generation EGFR tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with brain metastases
Simple Summary Targeted therapies have emerged as newer systemic options for certain
cancers. EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs), which have several …
cancers. EGFR-directed Tyrosine Kinase Inhibitors (EGFR-TKIs), which have several …
[HTML][HTML] Long-term survival of a non-small cell lung cancer patient with EGFR-mutated brain metastases: a case report
Y Wan, F Xu, J Wang - Translational Cancer Research, 2022 - ncbi.nlm.nih.gov
Background Lung cancer is the leading cause of cancer-related death worldwide. Up to 85%
of lung cancer is non-small cell lung cancer (NSCLC) and most patients present with …
of lung cancer is non-small cell lung cancer (NSCLC) and most patients present with …